Despite the prospect of vaccine availability in the near future: For virologists and epidemiologists there is no way around consistent testing to effectively contain the SARS-CoV-2 pandemic. The members of the DiagnostikNet-BB are active in this context, for example with
Test offers for members
validated sample and reference material
Basic components for PCR tests, enzymes primers and antibodies
new tests in different formats
The Institute for Molecular Diagnostics and Bioanalytics (IMDB) bundles and complements these offers as a provider of individual laboratory diagnostic services in the DiagnostikNet-BB. This creates synergies and accelerates innovation and product development.With its newly launched BMBF-funded project family, the IMDB sheds light on all aspects of SARS-CoV-2/COVID-19 diagnostics:
VALIDATE-Dx: assorts samples to form a cohort, which is backed by a complete anamnesis. Results of studies conducted with these samples are summarized and allow a comprehensive view of the disease process from genome to symptom.
PEPTIDE-Dx: provides individual epitope patterns of patients from different stages of the disease.
COMMUNICATE-Dx: systematically establishes digital contact with health authorities.
EPI-Dx: studies genomic variants of patient and virus.
TRAVEL-Dx: develops accelerated access to nucleic acid analysis as a PCR replacement for on-site diagnostics.
BEAD-Dx: creates the technological basis to correlate antibody data with autoimmune parameters.
DIRECT-Dx: investigates new ways to increase the sensitivity of antigen tests.
All projects are equipped with the VALIDATE-Dx cohort to generate valuable data for research and development of individualized test and therapy strategies. These are needed because Covid-19 is also a disease whose cure requires individual treatment methods.You are welcome to visit our joint booth at medica.diagnostiknet-bb.de